[Comparison of CHEP and CHOP chemotherapy in the management of non-Hodgkin's lymphoma].
OBJECTIVE
Therapeutic effect and toxicity of CHEP and CHOP chemotherapy in the treatment of non-Hodgkin's lymphoma (NHL) were compared.


METHODS
From October 1989 to June 1996, comparison of 52 NHL was carried out: CHEP (cyclophol-sphamide, adriamycin, etoposide, prednisone) group-26 patients and CHOP(cyclophosphamide, adriamycin, vincristine, prednisone) group-26 patients. The responses and toxicities were compared by the chi 2 test.


RESULTS
The CHEP group gave an overall response rate of 76.9%(20/26). In 10 untreated patients CR was observed in 7; The CHOP group gave an overall response rate of 65.4%(17/26). In 17 untreated patients CR was observed in 8(P > 0.05). Having been followed to the end of August, 1996, 16 patients in the CHEP group and 15 patients in the CHOP group were alive with respective median survivals 24(3-66) months and 20(2-48) months. Among the untreated patients, the 1-year disease-free survival (DFS) rates of those who gave CR were 70.0% and 23.5% (P < 0.05). 2-5 year DFS rats were 30%, 20%, 20%, 20%, and 11.8%, 5.9%, 5.9%, orespectively. The toxic reactions were tolerable in both groups.


CONCLUSIONS
In untreated NHL patients as treated with CHEP chemotherapy, 1-year DFS rate was superior to that of CHOP regimen (P < 0.05). Side toxicities were comparable in both groups, but no peripheral neuritis was observed in the CHEP group.
First People Hospital, Xiangtan.
J
J
Chen
Z
Z
Wang
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone